The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events. Although many genetic and nongenetic fac...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/8062796 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562143922225152 |
|---|---|
| author | Arwa M. Amin Lim Sheau Chin Dzul Azri Mohamed Noor Muhamad Ali SK Abdul Kader Yuen Kah Hay Baharudin Ibrahim |
| author_facet | Arwa M. Amin Lim Sheau Chin Dzul Azri Mohamed Noor Muhamad Ali SK Abdul Kader Yuen Kah Hay Baharudin Ibrahim |
| author_sort | Arwa M. Amin |
| collection | DOAJ |
| description | Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events. Although many genetic and nongenetic factors are known, great portion of clopidogrel variable platelets reactivity remain unexplained which challenges the personalization of clopidogrel therapy. Current methods for clopidogrel personalization include CYP2C19 genotyping, pharmacokinetics, and platelets function testing. However, these methods lack precise prediction of clopidogrel outcome, often leading to insufficient prediction. Pharmacometabolomics which is an approach to identify novel biomarkers of drug response or toxicity in biofluids has been investigated to predict drug response. The advantage of pharmacometabolomics is that it does not only predict the response but also provide extensive information on the metabolic pathways implicated with the response. Integrating pharmacogenetics with pharmacometabolomics can give insight on unknown genetic and nongenetic factors associated with the response. This review aimed to review the literature on factors associated with the variable platelets reactivity response to clopidogrel, as well as appraising current methods for the personalization of clopidogrel therapy. We also aimed to review the literature on using pharmacometabolomics approach to predict drug response, as well as discussing the plausibility of using it to predict clopidogrel outcome. |
| format | Article |
| id | doaj-art-f90581254e0b4605874d8caa78d7c056 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-f90581254e0b4605874d8caa78d7c0562025-02-03T01:23:21ZengWileyCardiology Research and Practice2090-80162090-05972017-01-01201710.1155/2017/80627968062796The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and PharmacometabolomicsArwa M. Amin0Lim Sheau Chin1Dzul Azri Mohamed Noor2Muhamad Ali SK Abdul Kader3Yuen Kah Hay4Baharudin Ibrahim5School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaCardiology Department, Hospital Pulau Pinang, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaDual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events. Although many genetic and nongenetic factors are known, great portion of clopidogrel variable platelets reactivity remain unexplained which challenges the personalization of clopidogrel therapy. Current methods for clopidogrel personalization include CYP2C19 genotyping, pharmacokinetics, and platelets function testing. However, these methods lack precise prediction of clopidogrel outcome, often leading to insufficient prediction. Pharmacometabolomics which is an approach to identify novel biomarkers of drug response or toxicity in biofluids has been investigated to predict drug response. The advantage of pharmacometabolomics is that it does not only predict the response but also provide extensive information on the metabolic pathways implicated with the response. Integrating pharmacogenetics with pharmacometabolomics can give insight on unknown genetic and nongenetic factors associated with the response. This review aimed to review the literature on factors associated with the variable platelets reactivity response to clopidogrel, as well as appraising current methods for the personalization of clopidogrel therapy. We also aimed to review the literature on using pharmacometabolomics approach to predict drug response, as well as discussing the plausibility of using it to predict clopidogrel outcome.http://dx.doi.org/10.1155/2017/8062796 |
| spellingShingle | Arwa M. Amin Lim Sheau Chin Dzul Azri Mohamed Noor Muhamad Ali SK Abdul Kader Yuen Kah Hay Baharudin Ibrahim The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics Cardiology Research and Practice |
| title | The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics |
| title_full | The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics |
| title_fullStr | The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics |
| title_full_unstemmed | The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics |
| title_short | The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics |
| title_sort | personalization of clopidogrel antiplatelet therapy the role of integrative pharmacogenetics and pharmacometabolomics |
| url | http://dx.doi.org/10.1155/2017/8062796 |
| work_keys_str_mv | AT arwamamin thepersonalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT limsheauchin thepersonalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT dzulazrimohamednoor thepersonalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT muhamadaliskabdulkader thepersonalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT yuenkahhay thepersonalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT baharudinibrahim thepersonalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT arwamamin personalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT limsheauchin personalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT dzulazrimohamednoor personalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT muhamadaliskabdulkader personalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT yuenkahhay personalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics AT baharudinibrahim personalizationofclopidogrelantiplatelettherapytheroleofintegrativepharmacogeneticsandpharmacometabolomics |